Skip to content

A Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter (AUS)

Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter In the treAtment of Stress Urinary Incontinence in Men

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06968741
Acronym
SOPHIA2
Enrollment
140
Registered
2025-05-13
Start date
2025-05-19
Completion date
2031-12-01
Last updated
2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Urinary Incontinence (SUI)

Keywords

Stress urinary incontinence, Artificial urinary sphincters

Brief summary

Prospective, multicenter, single-arm study

Interventions

DEVICEArtificial Urinary Sphincter (AUS)

AUS implant

Sponsors

UroMems SAS
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Key Inclusion Criteria: * Male subjects aged ≥ 22 years old * Able to read, comprehend and willing to sign an informed consent form * Primary diagnosis of stress urinary incontinence for at least 6 months, as assessed by the investigator * Appropriate surgical candidate with no medical or mental condition that would interfere with study procedures or confound study outcomes as assessed by the investigator Key

Exclusion criteria

* Currently enrolled or plans to enroll in another investigational device or clinical drug trial or has completed an investigational study (for urinary incontinence) in the past 3 months prior to informed consent * Poor candidate for surgical procedures and/or anesthesia, as determined by investigator * Currently implanted with an Active Implantable Medical Device (AIMD) * Symptoms or diagnosis of urge incontinence or mixed incontinence (MI) with a predominant urgency component, as assessed by the investigator

Design outcomes

Primary

MeasureTime frameDescription
Responder rate at 26 weeks post-activation26 weeksProportion of subjects who report greater than or equal to 50% reduction in the 24 hour Pad Weight Test (PWT) at 26 weeks compared with Baseline

Countries

France, United States

Contacts

CONTACTRoshini Jain
roshini.jain@uromems.com14697669888
STUDY_DIRECTORRoshini Jain

UroMems SAS

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026